文献速递肥胖与代谢综合征糖尿病

LLF580(FGF21类似物)降低肥胖成人甘油三酯和肝脏脂肪

LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in Obese Adults With Modest Hypertriglyceridemia.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

这项多中心双盲平行随机试验在肥胖伴轻度高甘油三酯血症成人中评估LLF580(人FGF21基因工程变体)的安全性及降低甘油三酯、减重和减少肝脏脂肪的潜力。64例参与者随机接受LLF580 300 mg或安慰剂皮下注射每4周一次共3次。结果显示LLF580显著降低血清甘油三酯、总胆固醇、LDL-C并升高HDL-C,同时大幅减少肝脏脂肪并改善肝损伤标志物,且胰岛素抵抗改善,总体安全耐受。

要点

  • LLF580降低甘油三酯54%、肝脏脂肪52%(安慰剂校正,P<0.001)
  • LLF580改善血脂谱并降低胰岛素抵抗,但空腹血糖和HbA1c无变化
  • LLF580总体安全,但胃肠道不良事件发生率较高,多为轻中度

核心结论

  • 在肥胖伴轻度高甘油三酯血症成人中,LLF580总体安全,并对血脂、肝脏脂肪和肝损伤标志物显示有益效应,可能对高甘油三酯血症和非酒精性脂肪性肝病等代谢疾病有效。

研究设计与样本

  • 多中心、双盲、平行设计试验,在美國7个研究中心纳入肥胖、轻度高甘油三酯血症成人,按1:1随机接受LLF580 300 mg或安慰剂皮下注射,每4周一次共3次。
  • 64例随机参与者中61例(平均年龄45±11岁,49%男性,80/15/5%白人/非裔美国人/其他,BMI 36.1±3.8 kg/m2)接受了LLF580(n=30)或安慰剂(n=31)。

主要发现

  • 与安慰剂相比,LLF580在12周内使血清甘油三酯降低54%(最小二乘均值安慰剂校正的基线变化),总胆固醇降低7%,LDL-C降低12%,HDL-C升高36%(均P<0.001)。
  • 与安慰剂相比,LLF580使肝脏脂肪减少52%(P<0.001),并改善丙氨酸氨基转移酶、天冬氨酸氨基转移酶、碱性磷酸酶、增强肝纤维化复合评分和III型前胶原N端肽(均P<0.05)。
  • 与安慰剂相比,LLF580治疗者胰岛素和C肽水平及HOMA-IR均更低,脂联素更高,而空腹血糖和糖化血红蛋白无变化。
  • 观察到骨形成标志物降低,但骨吸收标志物无差异。
  • LLF580总体安全且耐受良好,但胃肠道不良事件(一般为轻中度)发生率较高。

临床怎么用

  • LLF580可能作为高甘油三酯血症和非酒精性脂肪性肝病的候选治疗药物,但需更长期的安全性和有效性评估。

局限性

  • 样本量较小(61例接受治疗),干预和随访时间为12周,需更长期评估安全性和有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the safety and potential efficacy of LLF580, a genetically engineered variant of human fibroblast growth factor-21, for triglyceride lowering, weight loss, and hepatic fat reduction. METHODS: A multicenter, double-blind, parallel design trial in obese, mildly hypertriglyceridemic adults randomized (1:1) to LLF580 300 mg or placebo subcutaneously every 4 weeks for 3 doses. RESULTS: Of 64 randomized study participants, 61 (mean ± SD: age 45 ± 11 years, 49% male, 80/15/5% Caucasian/African American/other, body mass index 36.1 ± 3.8 kg/m2) received LLF580 (n = 30) or placebo (n = 31) at 7 research sites in the United States. LLF580 lowered serum triglycerides by 54% (least square mean placebo adjusted change from baseline), total cholesterol 7%, low-density lipoprotein cholesterol 12%, and increased high-density lipoprotein cholesterol 36% compared with placebo (all P < 0.001) over 12 weeks. Substantial reduction of liver fat of 52% over placebo (P < 0.001) was also demonstrated in the setting of improved liver function tests including alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase, the composite enhanced liver fibrosis score, and N-terminal type III collagen propeptide (all P < 0.05). Insulin and C-peptide levels and insulin resistance by homeostatic model assessment for insulin resistance were all lower, and adiponectin higher with LLF580 treatment compared with placebo, whereas fasting glucose and glycated hemoglobin were unchanged. Reductions in biomarkers of bone formation without differences in markers of bone resorption were observed. LLF580 was generally safe and well tolerated, except for higher incidence of generally mild to moderate gastrointestinal adverse effects. CONCLUSIONS: In obese, mildly hypertriglyceridemic adults, LLF580 was generally safe and demonstrated beneficial effects on serum lipids, liver fat, and biomarkers of liver injury, suggesting it may be effective for treatment of select metabolic disorders including hypertriglyceridemia and nonalcoholic fatty liver disease. Assessments of longer term safety and efficacy are warranted. CLINICALTRIALS.GOV IDENTIFIER: NCT03466203.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Rader DJ, Maratos-Flier E, Nguyen A, et al. LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in Obese Adults With Modest Hypertriglyceridemia. J Clin Endocrinol Metab. 2022. PMID: 34431493. doi:10.1210/clinem/dgab624

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。